Mi-mAbs is  an innovative integrated immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory diseases. 
Open to the best targets of academic and industrial research, MI-mAbs determines their expression profile, generates antibodies and validates them. A multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry , anatomopathology and in vitro / in vivo immunopharmacology has an objective to be the 1st integrated platform that generates and validates therapeutic antibodies. MI-mAbs contracts with research institutions, public technology transfer offices, or biotech companies



There are two parts to the Festival of Biologics: four conferences covering Antibodies, Immunotherapy, Biosimilars and Clinical Trials and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.